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Summary 
Cardiovascular disease (CVD) remains the most common cause of death in 
Europe and worldwide accounting for 31% of all deaths. Importantly, atherosclerosis is 
by far the most important cause of CVD, accounting for 80% atherosclerosis of CVD 
worldwide. Atherosclerosis is a lipid-driven chronic inflammatory disease, leading to 
the formation of plaques at vital segments of the arterial tree. Atherosclerotic plaques 
are deposits of cholesterol, lipids and cellular debris in the artery wall, resulting in 
narrowing of the larger arteries. Initial atherosclerotic lesions are characterized by 
subendothelial accumulation of macrophages and macrophage-derived foam cells. In 
progressive stages of disease development, medial smooth muscle cells will 
proliferate, migrate into the intima and produce collagen, forming a fibrous cap that 
covers the plaque (i.e. stable lesion). The vulnerable plaque is characterized by an 
extensive lipid core in the central atheroma, a high level of inflammation and 
a thin and inflamed fibrous cap covering the large necrotic core (thin-cap 
fibroatheromas; TFCA). In the final disease stage this vulnerable plaque will rupture 
leading to thrombus formation which can occlude the lumen causing distal ischemia 
and acute cardiovascular events (e.g. myocardial infarction (MI), stroke). 
Endothelial cells play an important role in maintaining cardiovascular 
homeostasis. In this thesis we have focused on the molecular regulators thereof. The 
aim of this thesis is two-fold: 1) to study endothelial cells (EC) dysfunction mediated by 
impaired NO in heart failure, and 2) to define new molecular regulators of lymphatic 
EC (LEC) in atherosclerosis. 
The first part of the thesis involves a study of endothelial dysfunction  in the 
heart and vessels, which is often characterized by impaired NO bioavailability, leading 
to vasoconstriction, coagulation and inflammation. When chronic, this can lead to 
several pathological conditions, including MI, hypertension and atherosclerosis. In this 
dissertation it is hypothesized that modulation of endothelial nitric oxide synthase 
(eNOS) can protect against pressure overload-induced left ventricular hypertrophy. 
 In the first part of this thesis (chapter 2-5) are focused on the molecular 
mechanism of eNOS and its essential cofactor tetrahydrobiopterin (BH4), as well as 
potential therapeutic interventions to modulate eNOS in the pathogenesis of 
myocardial and endothelial dysfunction.  As discussed in chapter 2, BH4 is a critical 
regulator of cardiovascular homeostasis, and substantial evidence implicates BH4 as 
a key regulator of eNOS in the setting of cardiovascular disease. Strategies to 
maintain BH4 bioavailability may be achieved by 1) enhancing the regeneration of 
BH4 from the inactive form BH2, 2) chemically stabilizing BH4, and 3) reducing 
oxidative degradation. Indeed, eNOS-generated NO has a crucial role in the regulation 
of endothelial function.  Chaper3 provides an extensive overview of the important role 
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of eNOS-uncoupling in the pathogenesis of endothelial dysfunction. Evidence 
suggests that modulation of eNOS by stabilizing eNOS function, and suppressing 
eNOS-derived ROS is a promising therapeutic target for endothelial dysfunction. 
Subsequently, in chapter 4, two, novel pharmacologic small molecule compounds that 
transcriptionally enhance eNOS gene expression, AVE9488 and AVE3085, are 
discussed. These compounds are designed to increase eNOS transcription and 
enhance NO signaling and bioavailability. Interestingly, AVE have been shown to also 
increase BH4 bioavailability reversing eNOS uncoupling, and to augment eNOS 
activity. Although their precise mode of action remains to be clarified, AVE are likely to 
interact with eNOS uncoupling. Subsequently, in chapter 5, we test if AVE3085 can 
prevent pressure overload-induced left ventricular (LV) hypertrophy. We have 
demonstrated that AVE 3085 attenuates the pathological LV changes caused by 
pressure overload. Surprisingly, these effects are seen in the absence of 
transcriptional upregulation of eNOS. Importantly, we provide a novel beneficial 
function of AVE3085 treatment on eNOS stability, demonstrating by an increase in 
eNOS dimer to monomer ratio and by a decrease in myocardial ROS generation. This 
effect is likely the result of protection of BH4 against oxidation by ROS. Possible 
mechanisms for AVE3085 mediate modulation/dampening of transverse aortic 
constriction -induced inflammatory responses and fibrosis may result from (I) indirect 
effects secondary to inhibition of macrophage infiltration and inflammatory signaling 
mediated by NO and/ or BH4, or (2) pleiotropic effects of AVE3085 on anti-
inflammatory and anti-fibrotic effect. 
The second part of this thesis is centered on the role of LEC in 
atherosclerosis. Angiogenesis, the sprouting of new blood vessels from the pre-
existing ones, is essential for physiological development. Pathological angiogenesis 
contributes to pathogenesis of cardiovascular diseases. Although plaque angiogenesis 
has been linked to proinflammatory and proatherosclerotic effects, lymphatic vessels 
have only recently been implicated in the pathogenesis of MI and atherosclerosis, 
where proper lymphatic drainage seemed to protect against disease. The lymphatic 
system is increasingly recognized as a critical process in atherosclerosis to transport 
cholesterol and immune cells to the lymph nodes and eventually to the circulation. 
However, the precise driving factors and consequences of lymphangiogenesis in the 
context of human atherosclerosis still remain to be elucidated. Plaque-resident 
factors specifically involved in pathologic lymphangiogenesis during atherosclerosis 
development and progression may well represent novel approaches for therapeutic 
modulation of plaque lymphangiogenesis. In this part, it is hypothesized that gene 
network analysis can provide powerful predictions of candidate genes and  those 
genes represent potential novel targets for regulating lymphangiogenesis-
associated atherosclerosis in human (approaches will be described below). 
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In chapter 6 we attempt to identify novel players in pathologic 
lymphangiogenesis in atherosclerosis. We employ a bioinformatics approach, 
weighted gene coexpression network analysis (WGCNA), to identify networks and 
candidate genes relevant to plaque lymphangiogenesis in humans. In this study, we 
correlate phenotypic traits i.e. LVD, identified by D2-40+ in human atherosclerotic 
tissue with transcription profiles, derived from the same tissue. We are able to identify 
modules with high correlation to LVD, unveiling a novel role for the phosphatase 
TNIP2, as a VEGF- independent key regulator of plaque lymphangiogenesis in 
humans ex vivo, in LEC in vitro and in zebrafish in vivo. In addition, we also provide 
transcription factor binding sites, miRNAs, and potential pathways which may be 
involved in TNIP2-mediated plaque lymphangiogenesis. TNIP2-responsive genes are 
enriched in lymphatic signature genes and suggest the involvement of type I/II IFN 
signaling, and lipid/cholesterol homeostatic regulation in TNIP2 functional effects.   
Finally, in chapter 7 we have discussed the most relevant findings of this 
thesis and provided the future perspectives. Altogether, this thesis affords novel 
insights into the molecular regulation of endothelial cells in CVD, with particular focus 
on eNOS and TNIP2. In conclusion, enhancement of functional eNOS can ameliorate 
endothelial and heart function in heart failure. In vessels, TNIP2 induction could 
represent an interesting target to stimulate plaque lymphangiogenesis, thereby 
promoting inflammation resolution in plaque. Considering the therapeutic potential of 
my findings we may conclude that (I) AVE3085 helps maintaining eNOS functionality 
and thus may improve eNOS/NO signaling dependent cardiovascular function, and (II) 
TNIP2 induction will increase lymphangiogenic responses in plaque, which could 
improve lymphatic drainage of constituents, cytokines and  inflammatory cells from 
plaque ,and  thus  may dampen atherosclerosis progression. Therefore, the next 
challenge is to translate these findings to clinical applications for cardiovascular 
diseases prevention and/or treatment. 
 
  
